1.
02
SURGERY 1
Hemostasis, Surgical Bleeding and Transfusion
Dr. Carlos Aleta, MD | 23 August 2017
Boxed areas (with dots) were taken from Schwartz 10th edition
I. STAGES OF VASOCONSTRICTION
Vascular constriction is the initial response to vessel injury.
● It is more pronounced in vessels with medial smooth muscles
and is dependent on the local contraction of smooth muscles.
● Subsequently linked to platelet plug formation.
● Substances released:
○ Thromboxane A2 (TXA2)
■ Produced locally at the site of injury via
release of arachidonic acid from platelet
membranes
■ A potent VASOCONSTRICTOR and has
platelet aggregation effects
○ Endothelin
■ Synthesized by injured endothelium
■ Potent VASOCONSTRICTOR
○ Serotonin (5-hydroxytryptamine, 5-HT)
■ Released during platelet aggregation
■ Potent VASOCONSTRICTOR
○ Bradykinin and Fibrinopeptides
■ Involved in coagulation scheme
■ Contraction of vascular smooth muscle
● The extent of vasoconstriction varies with the degree of vessel
injury.
● A small artery with a lateral incision may remain open due to
physical forces, whereas a similarly sized vessel that is
completely transected may contract to the extent that bleeding
ceases spontaneously.
II. PLATELET FUNCTION
● Platelets are anucleate fragments of megakaryocytes
● Normal circulating number of platelets: 150,000 - 400,000/µL
○ Up to 30% of circulating platelets may be
sequestered in the spleen;
○ if not consumed in a clotting reaction, platelets are
normally removed by the spleen and may have an
average lifespan: 7-10 days.
● Play an integral role in hemostasis by forming a hemostatic
plug (aids in cessation of bleeding during injury) and by
contributing to thrombin formation.
● Platelets do not normally adhere to each other or to the vessel
wall but can form a plug that aids in cessation of bleeding
when vascular disruption occurs
● Can be divided into:
○ primary wave/primary hemostasis
○ secondary wave/secondary hemostasis
PRIMARY HEMOSTASIS
● Platelet aggregation at this point is REVERSIBLE and is not
associated with secretion
● Heparin does not interfere with this reaction (thus, can occur
in a heparinized patient)
● ADP and Serotonin are the principal mediators of platelet
aggregation
1.02 | Surgery Batch 2020 Trans Team
● Arachidonic acid released from the platelet membrane is
converted by cyclooxygenase to prostaglandin G2 (PGG2),
which in turn is converted to prostaglandin H2 (PGH2).
PGH2 is further converted to thromboxane A2 (TXA2), a
potent vasoconstrictor and platelet aggregator. Arachidonic
acid may also be shuttled to adjacent endothelial cells and
converted to prostacyclin (PGI2), which is a vasodilator and
acts to inhibit platelet aggregation.
● NICE TO KNOW: Platelet COX
○ Irreversibly inhibited by Aspirin
○ Reversibly blocked by NSAIDs
○ Not affected by COX-2 inhibitors
SECONDARY HEMOSTASIS
● Release reaction results in compaction of the platelets into a
plug, a process that is no longer reversible.
● Fibrinogen
○ required cofactor of the process;
○ bridge for the GP IIb/IIIa receptor on the activated
platelets
● Substances released:
○ ADP, Ca+2, 5-HT, TXA2, α-granule proteins
○ Thrombospondin
- Secreted by α-granules
- Stabilizes fibrinogen binding to the
activated platelet surface
- Strengthens the platelet-platelet
interactions
○ Platelet factor 4 (PF4)
- Potent heparin antagonist
○ α-thromboglobulin
● Inhibited by aspirin, NSAIDs, cAMP, and NO
● As a consequence of the release reaction, alteration occurs in
the phospholipids of the platelet membrane that allow calcium
and clotting factors to bind to the platelet surface, forming
enzymatically active complexes.
● The altered lipoprotein surface (Platelet Factor 3)
○ Catalyzes reaction in the conversion of
prothrombin (Factor II) to thrombin (Factor IIa) by
activated Factor Xa in the presence of Factor V
and calcium.
○ Involved in the reaction by which activated Factor
IX (IXa), Factor VIII, and calcium activate factor
X.
● Platelets may also play a role in the initial activation of factors
XI and XII.
III. COAGULATION
● Depicted traditionally as 2 possible pathways, intrinsic and
extrinsic, converging into a common pathway
● Process and sequences that lead to a clot
1 of 11
 SURGERY 1
Hemostasis, Surgical Bleeding and Transfusion

Figure 1. Schematic diagram of coagulation system. HMW = high

molecular weight Figure 2. Plasmin’s role in fibrinolysis, its inhibitors (red) and activators
INTRINSIC PATHWAY
● No surface is needed; it is ”intrinsic” to the circulating plasma REGULATION MECHANISMS
● Begins with activation of XII which activates XI, IX and VIII 1. Plasmin is inhibited by α2-antiplasmin, a protein that is cross-
● Factor IXa is responsible for the bulk of conversion of X to Xa linked to fibrin by factor XIII, which helps to ensure that clot lysis
● VIIIa + IXa = intrinsic factor complex does not occur too quickly.
○ 50x more effective at catalyzing factor X than the 2. FDPs, like E-nodule and D-dimers, interfere with platelet
extrinsic (TF-VIIa) factor complex aggregation -> unstable clot
3. Thrombin-activatable fibrinolysis inhibitor (TAFI) removes
EXTRINSIC PATHWAY lysine residues from fibrin that are essential for binding
● Tissue Factor (TF) is released or exposed on the surface of plasminogen -> ⬇ fibrinolysis
the endothelium -> binds to circulating factor VII -> activated
to VIIa

COMMON PATHWAY
● Xa, Va, Ca+2 and phospholipid
○ Converts Factor II (prothrombin) to thrombin
● Thrombin
○ Factor I (fibrinogen) -> fibrin + Fibrinopeptides A & B
○ Activation of factors V, VII, VIII, XI, XIII

CLINICAL IMPORTANCE
● Prolonged aPTT (activated partial thromboplastin time)
signals abnormalities in the intrinsic and common pathways
(Factors II, VIII, IX, X, XI)
● Prolonged PT (prothrombin time) is associated with
abnormalities in the extrinsic and common pathways
(Factors II, VII, X)
● Vitamin K deficiency and use of Warfarin affect Factors II,
VII, IX, X (1972 - mnemonic)

IV. FIBRINOLYSIS
● Allows restoration of blood flow during the healing process
following injury Figure 2. Regulation of fibrinolysis. Note TAFI and a2-antiplasmin
● Begins at the same time as clot formation is initiated
● Plasmin: degrades fibrin polymers to fibrin degradation UROKINASE AND STREPTOKINASE
products (FDPs) STREPTOKINASE
● Bradykinin: potent endothelial-dependent vasodilator ● Group C hemolytic bacteria
○ Cleaved from HMW kininogen by kallikrein ● Plasminogen activator
○ Enhances the release of tPA ● Antigenic
● Plasminogen + tPA bind to fibrin as it forms and cleaves it UROKINASE
very efficiently. After plasmin is generated, it cleaves fibrin ● Isolated from urine, monocytes and macrophages, fibroblasts
less efficiently & epithelial cells.
● Degrades extracellular matrix to activate plasmin
● More efficient plasminogen activator
● Non antigenic

Co, Loyola, Geronimo, Jazul, Larracas, Macario, Macam, Villanueva, Samson, Sy, Cordova,
S1 T2 | Barbosa, dela Torre, Soriano
2 of 11
 SURGERY 1
Hemostasis, Surgical Bleeding and Transfusion
CLINICAL IMPORTANCE
● Thrombolytic
○ Acute Myocardial Infarction
○ Acute Pulmonary Embolism
● These are avoided during acute post-op period due to
bleeding
○ prescription must be exactly equivalent to the
patient’s weight
V. CONGENITAL HEMOSTATIC DEFECTS
COAGULATION FACTOR DEFICIENCIES
● Deficient Factor VIII – most frequent
○ Hemophilia A
○ Von Willebrand’s Disease
● Deficient Factor IX - Hemophilia B (Christmas Disease)
● Hemophilia
○ Have severe spontaneous bleeding
○ Intramuscular hematomas, retroperitoneal
hematomas, and GI, genitourinary, and
retropharyngeal bleeding
○ Intracranial bleeding and bleeding from the tongue
or lingual frenulum
HEMOPHILIA A AND B
● Sex-linked recessive disorders, males being affected almost
exclusively
● Clinical severity depends on the measurable level of Factor
VIII or Factor IX in the patient’s plasma
○ Levels < 1% of normal – considered severe
○ Levels between 1% - 5% - moderately severe
○ Levels between 5% - 30% - mild
CLINICAL PICTURE
Severe hemophilia
● Spontaneous bleeds, frequently into joints, leading to
crippling arthropathies
● Intracranial bleeding
● Intramuscular hematomas
● Retroperitoneal hematomas
● Gastrointestinal, genitourinary & retropharyngeal
bleeding
Moderately severe hemophilia
● Less spontaneous bleeding but are likely to bleed
severely after trauma or surgery
Mild hemophilia
● Do not bled spontaneously and have only minor
bleeding after major trauma or surgery
Treatment: factor VIII or IX concentrate
● recombinant factor VIII: strongly recommended for
patients previously untreated and for HIV and hepatitis
C-seronegative patients
● recombinant or high-purity factor IX
VON WILLEBRAND DISEASE
● Most common congenital bleeding disorder.
● Characterized by a quantitative or qualitative defect in
vWF
● Responsible for carrying Factor VIII and platelet
adhesion
- Easy bruising and mucosal bleeding
- Menorrhagia is common in women
- May also have low levels of Factor VIII
● Three types
○ Type I – partial quantitative deficiency; respond
well to desmopressin (DDVAP)
○ Type II – qualitative defect, may/may not
respond to DDVAP
○ Type III – total deficiency, does not respond to
DDVAP
Co, Loyola, Geronimo, Jazul, Larracas, Macario, Macam, Villanueva, Samson, Sy, Cordova,
S1 T2 | Barbosa, dela Torre, Soriano
HEMOPHILIA C / FACTOR XI DEFICIENCY
● An autosomal recessive inherited condition
● More prevalent in the Ashkenazi Jewish population but
found in all races
● Spontaneous bleeding is rare
● But bleeding may occur after surgery, trauma, or
invasive procedure
● Tx – fresh frozen plasma (FFP)
○ Antifibrinolytics – for patients with menorrhagia
○ Factor VIIa – for patients with anti-factor XI
antibodies
DEFICIENCY OF FACTOR II, V, AND X
● Rare; autosomal recessive
● Treatment: FFP
○ Prothrombin complex concentrates – for factor II
or factor X deficiency
○ Factor V deficiency may be co-inherited with
factor VIII deficiency - treatment requires factor
VIII concentrate and FFP (others require platelet
transfusions)
FACTOR VII DEFIECIENCY
● Rare autosomal recessive
● Does not always correlate with the level of FVII
coagulant activity in plasma
● Bleeding is uncommon unless the level is less than 3%
● Most common bleeding manifestations:
o easy bruising
o mucosal bleeding (epistaxis or oral mucosal
bleeding)
● Postoperative bleeding is also common
● Treatment: FFP or recombinant factor VIIa
FACTOR XIII DEFICIENCY
● Rare autosomal recessive
● Associated with severe bleeding diathesis
● Occurrence (Male to female) - 1:1
● Manifestations
○ delayed bleeding because clots formed
normally are susceptible to fibrinolysis
○ umbilical stump bleeding
○ high risk of intracranial bleeding
● Treatment: FFP, cryoprecipitate, or factor XIII
concentrate
VI. PLATELET FUNCTIONAL DEFECTS
● Include abnormalities of platelet surface proteins,
abnormalities of platelet granules, and enzyme defects
SURFACE PROTEIN ABNORMALITIES
THROMBASTHENIA
● Glanzmann thrombasthenia
● Inherited in an autosomal recessive pattern
● Platelet glycoprotein IIb/IIIa complex is either lacking or
present but dysfunctional -> faulty platelet aggregation ->
bleeding
● Treatment: platelet transfusions
BERNARD SOULIER SYNDROME
● Defect in the glycoprotein Ib/IX/V receptor for vWF, which is
necessary for platelet adhesion to the subendothelium
● Treatment: platelet transfusions
STORAGE POOL DISEASE
● Most common intrinsic platelet defect
● Loss of dense granules and alpha-granules
● Dense granule deficiency is the most prevalent
3 of 11
 SURGERY 1
Hemostasis, Surgical Bleeding and Transfusion
● Maybe isolated or occur with partial albinism in the
Hermansky-Pudlak syndrome
● Bleeding is variable to the granule defect
● Bleeding is caused by decreased release of ADP from these
platelets
● Treatment: Desmopressin (DDAVP), platelet transfusion
for more severe bleeding
VII. ACQUIRED HEMOSTATIC DEFECTS
A. PLATELET ABNORMALITIES
1. QUANTITATIVE DEFECTS
FAILURE OF PRODUCTION
● Failure of production is usually due to impairment in bone
marrow function like
○ Leukemia
○ Myeloproliferative disorders
○ B12 or folate deficiencies
○ Chemotherapy or radiation therapy
○ Acute alcohol intoxication
○ Viral infections
DECREASED SURVIVAL
● Shortened platelet survival is seen in
○ Immune-mediated
■ Idiopathic thrombocytopenia
■ Heparin-induced thrombocytopenia
■ Auto-immune disorders or B-cell
malignancies
■ Secondary Thrombocytopenia
○ Disseminated Intravascular Coagulation (DIC)
○ Disorders characterized by platelet thrombi
■ Thrombocytopenic purpura
■ Hemolytic uremic syndrome
Primary Immune Thrombocytopenia
● Idiopathic thrombocytopenic purpura (ITP)
● Acute and short lived and follows viral infection
● ITP in adults is gradual in onset, chronic, and idiopathic
● Involve both impaired platelet production and T cell-mediated
platelet destruction
● 1-2 days if heparin is a re-exposure HIT if platelet count
<100,000 or 50% drop from baseline in a patient receiving
heparin
● More common with full-dose unfractioned heparin but can also
occur with prophylactic dose and LMW heparin.
● Diagnosed using serotonin release assay(SRA) or ELISA
○ SRA - highly specific but not sensitive
○ ELISA - low specificity
● Serotonin release assay is highly specific but not sensitive i.e.
confirmatory Dx
● Negative ELISA result essentially rules out HIT
● Tx: heparin cessation and alternative coagulants
● Heparin cessation without coagulant alternative may result
into thrombosis
Thrombotic Thrombocytopenic Purpura (Ttp)
● large vWF molecules interact with platelets, leading to
activation
● Large molecules result from inhibition of a metalloproteinase
enzyme, ADAMTS13, which cleaves large vWF
● Characterized by thrombocytopenia, microangiopathic
hemolytic anemia, fever, renal and neurologic signs and
symptoms
● Tx: plasma exchange with FPP replacement (acute),
rituximab
Hemolytic Uremic Syndrome
● Secondary to infection by E. coli or Shiga toxin-producing
bacteria
● Associated with some degree of renal failure, with many
patients requiring renal replacement therapy
● Patients develop features of both TTP and HUS
● Autoimmune diseases, especially lupus erythematosus, and
HIV infection, or in association with certain drugs (ticlopidine,
mitomycin C, gemcitabine), and immunosuppressive agents
(cyclosporine and tacrolimus)
● Tx: Plasmapheresis
SEQUESTRATION
● involves trapping of platelets in an enlarged spleen
● related to portal HTN, sacroid lymphoma or Gaucher’s
disease
● Decreased platelet survival and and less anticipation for
bleeding since sequestered platelets can still be mobilized to
some extent
● Splenectomy doesn’t correct thrombocytopenia of
hypersplenism caused by portal HTN

Heparin Induced Thrombocytopenia (Hit)
● Drug induced, due to antibodies for platelet factor 4 produced
during heparin exposure affect platelet activation and
endothelial function.
● Results to thrombocytopenia and intravascular thrombosis w/
high incidence of thrombosis either arterial or venous
● Platelet count decreases 5-7 days after heparin administration
THROMBOCYTOPENIA
● most common abnormality of hemostasis
● bone marrow usually demonstrate normal or increased
number of megakaryocytes; reduced if patient is uremic or has
leukemia or under cytotoxic therapy
● In contrast, there are generally a reduced number of
megakaryocyte in the marrow for leukemia and uremia px.
● Occurs in surgical patients as a result of massive blood loss
and replacement with product deficient in platelets
● Platelets are administered preoperatively to rapidly increase
the platelet count in surgical patients with underlying
thrombocytopenia
● Fever, infection, hepatosplenomegaly, and the presence of
anti-platelet alloantibodies decrease the effectiveness of
platelet transfusions
● Patients whose thrombocytopenia is refractory to standard
platelet transfusion, the use of human leukocyte antigen
(HLA) compatible platelets coupled with special processors
has proved effective

Co, Loyola, Geronimo, Jazul, Larracas, Macario, Macam, Villanueva, Samson, Sy, Cordova,
S1 T2 | Barbosa, dela Torre, Soriano
4 of 11
 SURGERY 1
Hemostasis, Surgical Bleeding and Transfusion
2. QUALITATIVE DEFECTS
● Impaired function
● Impairment of ADP-stimulated aggregation that occurs with
massive transfusion of blood products
○ Uremia may be associated with increased bleeding
time and impaired aggregation.
○ Seen in patients with thrombocytopenia,
polycythemia vera and myelofibrosis
● Drug interference with platelet function such as aspirin,
clopidogrel, prasugrel, dipyridamole, and GP IIb/IIIa inhibitors
○ Clopidogrel and pasugrel are selective ADP-
irreversible inhibitors
○ Aspirin - irreversible COX inhibitor stopping TXA2
synthesis
B. ACQUIRED HYPOFIBRINOGENEMIA
Disseminated Intravascular Coagulopathy(DIC)
● Characterized by systemic activation of coagulation pathway
resulting to excessive thrombin generation and diffuse
formation of microthrombi
● Ultimately leads to consumption and depletion of platelets and
coagulation factors -> diffuse bleeding
● Fibrin microthrombi may lead to microvascular ischemia and
end-organ failure
● Injuries resulting in embolization of materials such as brain
matter, bone marrow, or amniotic fluid can act as potent
thromboplastins that activate the DIC cascade.
● DIC frequently accompanies sepsis and may be associated
with multiple organ failure.
● Diagnosis of DIC is made based on an inciting etiology with:
○ associated thrombocytopenia,
○ prolongation of the prothrombin time
○ a low fibrinogen level
○ elevated fibrin markers (FDPs, D-dimer, soluble
fibrin monomers)
● Most important facets of treatment includes relieving the
primary medical/surgical problems and maintaining adequate
perfusion.
○ If there is active bleeding -> replace hemostatic
factors with FPP; can suffice but may also need
cryoprecipitates, fibrinogen concentrates or platelet
concentrates.
○ Heparin is not really helpful in acute forms but may
be indicated in cases where thrombosis is
predominant
Primary Fibrinolysis
● Acquired hypofibrinogenic state in the surgical patient can be
a result of pathologic fibrinolysis
● may occur in patients following prostate resection when
urokinase is released during surgical manipulation of the
prostate or in patients undergoing extracorporeal bypass.
● fibrinolytic bleeding is dependent on the concentration of
breakdown products in the circulation.
● Tx: Antifibrinolytic agents, such as ε-aminocaproic acid and
tranexamic acid
C. MYELOPROLIFERATIVE DISEASE
● Polycythemia, particularly with marked thrombocytosis,
presents a major surgical risk
● Operation should only be considered in most grave surgical
emergencies
● Operation should be deferred until medical management has
restored normal blood volume, hematocrit level, and platelet
count
● Spontaneous thrombosis is a complication of polycythemia
vera
● Could be explained in part by increased blood viscosity,
increased platelet count, and an increased tendency toward
stasis
● Significant tendency toward spontaneous hemorrhage also is
noted in these patients
Co, Loyola, Geronimo, Jazul, Larracas, Macario, Macam, Villanueva, Samson, Sy, Cordova,
S1 T2 | Barbosa, dela Torre, Soriano
● Most of the patients with myeloid metaplasia are post
polycythemic
● Thrombocytosis can be reduced by the administration of
hydroxyurea or anagrelide
● Phlebotomy and blood replacement with lactated Ringer’s
solution may be beneficial during emergency situations
D. COAGULOPATHY OF LIVER DISEASE
● The liver plays a key role in hemostasis because it is
responsible for the synthesis of many of the coagulation
factors
○ Patients with liver disease, therefore, have
decreased production of several key non-
endothelial cell-derived coagulation factors as well
as natural anticoagulant proteins.
○ causes a disturbance in the balance between
procoagulant and anticoagulant pathways.
● Disturbance in coagulation mechanism causes both
increased bleeding risk and thrombotic risk
● Thrombocytopenia and impaired humoral coagulation
manifested by increased PT and INR - most common
coagulation abnormality
● Thrombocytopenia in patients with liver disease is typically
related to hypersplenism, reduced production of
thrombopoietin, and immune-mediated destruction of
platelets.
● Thrombopoietin, the primary stimulus for thrombopoiesis, may
be responsible for some cases of thrombocytopenia in
cirrhotic patients, although its role is not well delineated.
● Immune-mediated thrombocytopenia may also occur in
cirrhotics, especially those with hepatitis C and primary biliary
cirrhosis
○ In addition to thrombocytopenia, these patients also
exhibit platelet dysfunction via defective
interactions between platelets and the endothelium,
and possibly due to uremia and changes in
endothelial function in the setting of concomitant
renal insufficiency.
● In conditions mimicking intravascular flow, low hematocrit and
low platelet counts contributed to decreased adhesion of
platelets to endothelial cells, although increased vWF, a
common finding in cirrhotic patients, may offset this change in
patients with cirrhosis
● Hypercoagulability of liver has gained increased attention
○ increased incidence of thromboembolism despite
thrombocytopenia and a hypocoagulable state on
conventional blood tests.
○ Attributed to decreased production of liver-
synthesized proteins C and S, antithrombin, and
plasminogen levels, as well as elevated levels of
endothelial-derived vWF and factor VIII, a potent
driver of thrombin generation.
○ Given the concomitant hypo- and hypercoagulable
features seen in patients with liver disease,
conventional
○ coagulation tests may be difficult to interpret, and
alternative tests such as thromboelastography
(TEG) may be more informative of the functional
status of clot formation and stability in cirrhotic
patients.
● Before instituting any therapy to ameliorate
thrombocytopenia, the actual need for correction should be
strongly considered.
○ correction based solely on a low platelet count
should be discouraged.
● Platelet transfusions are the mainstay of therapy; however,
the effect typically lasts only several hours.
○ Risk include development of antiplatelet antibodies
● A potential alternative strategy involves administration of
interleukin-11 (IL-11), a cytokine that stimulates proliferation
of hematopoietic stem cells and megakaryocyte progenitors
5 of 11
 SURGERY 1
Hemostasis, Surgical Bleeding and Transfusion
● Decreased production or increased destruction of coagulation
factors as well as vitamin K deficiency can all contribute to a
prolonged PT and INR in patients with liver disease.
E. COAGULOPATHY OF TRAUMA
● One- third of injured patients have evidence of coagulopathy
at the time of admission
● Traditional teaching regarding trauma-related coagulopathy
attributed its development to acidosis, hypothermia, and
dilution of coagulation factors.
● Acute coagulopathy of trauma(ACoT)
○ not a simple dilutional coagulopathy but a complex
problem with multiple mechanisms.
○ Key initiators are shock and tissue injury
○ Only patients in shock arrive coagulopathic and that
it is the shock that induces coagulopathy through
systemic activation of anticoagulant and fibrinolytic
pathways
F. ACQUIRED COAGULATION INHIBITION
● Antiphospholipid syndrome (APLS) - most common
acquired coagulation inhibition
o Lupus anticoagulant and anticardiolipin antibodies:
maybe associated with venous or arterial thrombosis or
both
o Very common in systemic lupus erythematosus (SLE)
but maybe seen in rheumatoid arthritis and Sjogren’s
syndrome
 Px have no autoimmune disorders but
develop transient Ab in response to infections
or who develop drug-induced APLS
o Hallmark: prolonged aPTT in vitro but increased risk of
thrombosis in vivo
G. PARAPROTEIN DISORDERS
● Production of an abnormal globulin or fibrinogen that
interferes with clotting or platelet function
● May be an IgM in Waldenstrom’s macroglobulinemia, an IgG
or IgA in multiple myeloma, a cryoglobulin in liver disease (hep
C) or autoimmune diseases, or a cryofibrinogen
● Tx: Chemotherapy (lowers the level of paraproteins in
macroglobulinemia and myeloma); plasmapheresis (remove
cryoglobulins and cryofibrinogens)
Co, Loyola, Geronimo, Jazul, Larracas, Macario, Macam, Villanueva, Samson, Sy, Cordova,
S1 T2 | Barbosa, dela Torre, Soriano
VIII. ANTICOAGULATION AND BLEEDING
ANTICOAGULATION
● Spontaneous bleeding can be a complication of any
anticoagulant therapy whether it is heparin, low molecular
weight-heparins, warfarin, factor Xa inhibitors, or new direct
thrombin inhibitors
● Risk of spontaneous bleeding is reduced with continuous
infusion technique
● Therapeutic anticoagulation is more reliably achieved with a
low molecular weight heparin
○ However, laboratory testing is more challenging
with these medications, as they are not detected
with conventional coagulation testing
● If monitoring is required (e.g., in the presence of renal
insufficiency or severe obesity), the drug effect should be
determined with an assay for anti-Xa activity.
● Warfarin:
○ for long-term anticoagulation in various clinical
conditions including:
■ deep vein thrombosis, pulmonary
■ embolism,
■ valvular heart disease,
■ atrial fibrillation, recurrent
■ systemic emboli
■ recurrent myocardial infarction,
■ prosthetic heart valves,
■ prosthetic implants.
○ Dec. effect when co administered with barbiturates
due to P450 interaction (dose must be inc.)
○ Inc. dose is also required inpatients taking
contraceptives or estrogen-containing compounds,
corticosteroids, and adrenocorticotropic hormone
○ Reversible with vitamin K
■ Urgent reversal for life-threatening
bleeding should include vitamin K and a
rapid reversal agent such as plasma or
prothrombin complex concentrate.
● Newer anticoagulants like dabigatran and rivaroxaban have
no readily available method of detection of the degree of
anticoagulation.
○ Also has no reversing agent
○ only possible strategy to reverse the coagulopathy
○ associated with dabigatran may be emergent
dialysis
○ Recent data suggest that rivaroxaban, however,
may be reversed with the use of prothrombin
complex concentrates (four-factor concentrates
only: II, VII, IX, and X).
● Bleeding complications in patients on anticoagulants include:
○ hematuria,
○ soft tissue bleeding,
○ intracerebral bleeding,
○ skin necrosis
○ abdominal bleeding
BLEEDING
● Bleeding secondary to anticoagulation therapy is also not an
uncommon cause of a rectus sheath hematomas.
● It is important to remember that symptoms of an underlying
tumor may first present with bleeding while on anticoagulation
● When the aPTT is less than 1.3 times control in a heparinized
patient or when the INR is less than 1.5 in a patient on
warfarin, reversal of anticoagulation therapy may not be
necessary
● Protamine is used for rapid reversal of heparin, however,
adverse reactions may occur in patients with severe fish
allergy
○ Symptoms include hypotension, flushing,
bradycardia, nausea, and vomiting
6 of 11
 SURGERY 1
Hemostasis, Surgical Bleeding and Transfusion
● Prolongation of the aPTT after heparin neutralization with
protamine may also be a result of the anticoagulant effect of
protamine.
● In the elective surgical patient who is receiving coumarin-
derivative therapy sufficient to effect anticoagulation, the drug
can be discontinued several days before operation and the
prothrombin concentration then checked (a level >50% is
considered safe).
● Parenteral administration of vitamin K also is indicated in
elective surgical treatment of patients with biliary obstruction
or malabsorption who may be vitamin K deficient.
○ if low levels of factors II, VII, IX, and X (vitamin K–
dependent factors) exist as a result of
hepatocellular dysfunction, vitamin K administration
is ineffective
IX. CARDIOPULMONARY BYPASS
● In patients undergoing cardiopulmonary bypass (CPB),
contact with circuit tubing and membranes results in abnormal
platelet and clotting factor activation, activation of
inflammatory cascades also occurs, ultimately resulting in
excessive fibrinolysis and a combination of both quantitative
and qualitative platelet defects.
● Platelets undergo reversible alterations in morphology and
their ability to aggregate, which causes sequestration in the
filter, partially degranulated platelets, and platelet fragments.
○ This multifactorial coagulopathy is compounded by
the effects of shear stress in the system, induced
hypothermia, hemodilution, and anticoagulation.
● While on pump, activated clotting time measurements are
obtained along with blood gas measurements;
● However, conventional coagulation assays and platelet
counts are not normally performed until rewarming and after
a standard dose of protamine has been given.
○ Thromboelastogram(TEG) may give a better
estimate of the extent of coagulopathy and may
also be used to anticipate transfusion requirements
if bleeding is present
● Empiric treatment with FFP and cryoprecipitate is often used
for bleeding patients
○ No universal accepted transfusion threshold though
● Platelet concentrates are given for bleeding patients in the
immediate postoperative period
● Many institutions now use antifibrinolytics, such as ε-
aminocaproic acid and tranexamic acid, at the time of
anesthesia induction after several studies have shown that
such treatment reduced postoperative bleeding and
reoperation.
● Aprotinin - a protease inhibitor that acts as an antifibrinolytic
agent, has been shown to reduce transfusion requirements
associated with cardiac surgery.
● Desmopressin acetate stimulates release of factor VIII from
endothelial cells and may also be effective in reducing blood
loss during cardiac surgery.
● Recombinant factor VIIa - last resort
X. TESTS FOR HEMOSTASIS AND BLEEDING
● Platelet count, PT/INR and aPTT are most common
● Normal platelet count - 150,000 - 400,000/microliter
○ >1,000,000/microliter - associated with bleeding or
thrombotic complication
● increased bleeding complications may be observed with major
surgical procedures when the platelets are below 50,000/μL
○ Observed at minor surgical procedures when
counts are below 30,000/μL
○ Spontaneous hemorrhage can occur when the
counts fall below 20,000/μL.
● PT reagent contains thromboplastin and calcium that, when
added to plasma, leads to the formation of a fibrin clot.
○ measures the function of factors I, II, V, VII, and X
Co, Loyola, Geronimo, Jazul, Larracas, Macario, Macam, Villanueva, Samson, Sy, Cordova,
S1 T2 | Barbosa, dela Torre, Soriano
○ Factor VII has the shortest half-life of the
coagulation factors, and its synthesis is vitamin K
dependent. Thus, suited to detect abnormal
coagulation caused by vitamin K deficiencies and
warfarin therapy
● Due to variations in thromboplastin activity, it can be difficult
to accurately assess the degree of anticoagulation on the
basis of PT alone. Thus, International Normalized Ratio
(INR) is now the method of choice for reporting PT values
○ INR = (measured PT/normal PT)^IS
■ ISI = International Sensitivity Index
■ Unique to each batch of thromboplastin
and is furnished by the manufacturer to
the hematology laboratory.
■ Optimal reagent has an ISI between 1.3
and 1.5.
● aPTT reagent contains a phospholipid substitute, activator,
and calcium, which in the presence of plasma leads to fibrin
clot formation.
○ measures function of factors I, II, and V of the
common pathway and factors VIII, IX, X, and XII of
the intrinsic pathway.
○ Heparin therapy is often monitored by following
aPTT values with a therapeutic target range of 1.5
to 2.5 times the control value (approximately 50 to
80 seconds).
○ Low molecular weight heparins are selective Xa
inhibitors that may mildly elevate the aPTT
● Bleeding time - used to evaluate platelet and vascular
dysfunction
○ The Ivy method is most commonly used
■ conducted by placing a
sphygmomanometer on the upper arm
and inflating it to 40 mmHg
■ a 5-mm stab incision is made on the
flexor surface of the forearm
■ time is measured to cessation of
bleeding, and the upper limit or normal
bleeding time with the Ivy test is 7
minutes
○ Abnormal bleeding time suggests platelet
dysfunction (intrinsic or drug-induced), vWD, or
certain vascular defects
● Medications may significantly impair hemostatic function,
such as:
○ antiplatelet agents (clopidogrel and GP IIb/IIIa
inhibitors),
○ anticoagulant agents (hirudin, chondroitin sulfate,
dermatan sulfate)
○ thrombolytic agents (streptokinase,tPA)
● These conventional tests do not reflect complexity of in vivo
coagulation
○ Useful in following warfarin and heparin therapy but
poorly reflect the status of actively bleeding patient
● Thromboelastogram(TEG)
○ better assess the complex and rapidly changing
interactions of an actively bleeding patient
○ monitors hemostasis as a dynamic process rather
than revealing information of isolated conventional
coagulation screens
○ measures the viscoelastic properties of blood as it
is induced to clot under a low-shear environment
(resembling sluggish venous flow)
○ patterns of change in shear-elasticity enable the
determination of the kinetics of clot formation and
growth as well as the strength and stability of the
formed clot
○ strength and stability provide information about the
ability of the clot to perform the work of hemostasis,
○ kinetics determines the adequacy of quantitative
factors available for clot formation
7 of 11
 SURGERY 1
Hemostasis, Surgical Bleeding and Transfusion
○ Parameters
■ r-value (reaction time)
- the time between the start of the assay
and initial clot formation. Reflects clotting
factor activity and initial fibrin formation,
increased with factor deficiency or severe
hemodilution
■ k-time (clot kinetics)
- time needed to reach specified clot
strength represents the interactions of
clotting factors and platelets, prolonged
with hypofibrinogenemia and significant
factor deficiency
■ Alpha or angle (∝)
- the slope of the tracing and reflects clot
acceleration. Reflects the interactions of
clotting factors and platelets. Decreased
with hypofibrinogenemia and platelet
dysfunction
■ Maximal amplitude(mA)
- the greatest height of the tracing and
represents clot strength. Its height is
reduced with dysfunction or deficiencies
in platelets or fibrinogen
■ G-value
- parametric measure derived from the mA
value and reflects overall clot strength or
firmness. An increased G-value is
associated with hypercoagulability,
whereas a decrease is seen with
hypocoagulable states.
■ LY30
- amount of lysis occurring in the clot, and
the value is the percentage of amplitude
reduction at 30 minutes after mA is
achieved. The LY30 represents clot
stability and when increased fibrinolysis
is present.
○ Prolonged r-value and k-time are commonly
addressed with plasma transfusions
○ Decreased angles are treated with cryoprecipitate
transfusion or fibrinogen administration.
○ Decreased mA is addressed with platelet
transfusion and, in cases where the angle is also
decreased, with cryoprecipitate (or fibrinogen) as
well.
XI. EVALUATION FOR INTRA- AND POST-OPERATIVE BLEEDING
● Excessive bleeding during or after a surgical procedure may
be due to
○ Ineffective hemostasis
○ Blood transfusion
○ undetected hemostatic effect
○ consumptive coagulopathy
○ fibrinolysis
● Massive blood transfusion is a well-known cause of
thrombocytopenia, this may also cause:
○ Bleeding following massive transfusion due to
hypothermia, dilutional coagulopathy, platelet
dysfunction, fibrinolysis, or hypofibrinogenemia.
● Hemolytic transfusion reactions characterized by bleeding
after transfusion, is due to the ADP release from hemolyzed
red blood cells, resulting in diffuse platelet aggregation, and
removal of platelet clumps out of the circulation.
● Transfusion purpura is an uncommon cause of
thrombocytopenia which occurs when donor platelets are of
an uncommon PlA1 group
○ The platelets sensitize the recipient, who then
makes antibodies against the foreign platelet
antigen
Co, Loyola, Geronimo, Jazul, Larracas, Macario, Macam, Villanueva, Samson, Sy, Cordova,
S1 T2 | Barbosa, dela Torre, Soriano
○ Foreign platelet antigen attaches to recipients
platelets, making them a target for destruction
● Disseminated Intravascular Coagulation (DIC) is
characterized by activation of the coagulation system and
causes the deposition of fibrin clots, and microvascular
ischemia, leading to multiple organ failure
○ Ongoing activation of the coagulation system may
induce severe bleeding complications due to
consumption and subsequent exhaustion of
coagulation proteins and platelets.
● Severe hemorrhagic disorders due to gram negative sepsis
inducing thrombocytopenia.
○ Defibrination and hemostatic failure -
Meningococcemia, Clostridium perfringens sepsis,
and staphylococcal sepsis
XII. LOCAL HEMOSTASIS
● Significant surgical bleeding is usually caused by ineffective
hemostasis
● Hemostasis may be accomplished by interrupting the flow of
blood to the involved area or by direct closure of the blood
vessel wall defect, and thus preventing further bleeding
MECHANICAL PROCEDURES
● Digital pressure - oldest method; applied to at the site of
bleeding or proximally to permit a definitive action
○ Effective and less traumatic than hemostatic or
“atraumatic” clamps
● Ligation - for smaller vessels
○ For large pulsating arteries, transfixation suture is
indicated to prevent slipping
THERMAL AGENTS
● Hemostasis by heat denaturation of protein which results in
coagulation
● Electrocautery - heat by induction from an alternating current
source, transmitted via conduction from the instrument directly
to the tissue
○ Amplitude is high enough to cause coagulation but
not exceedingly high to prevent thermal injury
outside the operative field and prevent exit of
current through ECG leads, monitoring devices,
permanent pacemakers, or defibrillators
○ A negative grounding plates should be placed
beneath the patient to avoid severe skin burns, and
caution should be used with certain anesthetic
agents (diethyl ether, divinyl ether, ethyl chloride)
due to explosion hazard.
TOPICAL HEMOSTATIC AGENTS
● Play an important role in facilitating surgical hemostasis
● Ideal hemostatic agent has: significant hemostatic action,
minimal tissue reactivity, non-antigenicity, in vivo
biodegradability, ease of sterilization, low cost, and tailored for
specific needs
● Not a substitute for meticulous surgical techniques
● Different agent (seen in the succeeding bullets) advantages
and disadvantages must be considered to minimize toxicity,
adverse reactions, interference with wound healing, and
procedural costs
● Absorbable agents
○ Gelatin foams (Gelfoam) and oxidized cellulose
(Surgicel) - physical matrix for clotting initiation
○ Microfibrillar collagen (Avitene) - platelet adherence
and activation
● Biologic agents
○ Topical thrombin (human or recombinant) - facilitate
activation of clotting factors and formation of fibrin
clots without inflammatory, foreign body reactions
■ Cation must be exercised since entry of
thrombin in large caliber vessels can
8 of 11
 SURGERY 1
Hemostasis, Surgical Bleeding and Transfusion
result to systemic exposure to thrombin
leading to DIC or death
○ Fibrin sealants (FloSeal) - prepared from
cryoprecipitate (homologous or synthetic) and have
the advantage of not promoting inflammation or
tissue necrosis
○ Platelet sealants (Vitagel) - mixture of collagen and
thrombin combined with plasma-derived fibrinogen
and platelets from the patient
XIII. TRANSFUSION
HISTORY
● Human blood replacement therapy was accepted in the late
nineteenth century
● 1900 - Karl Landsteiner - Introduction of blood grouping
(A,B,O); resulting in widespread use of blood products in WWI
● 1939 - Levine and Stetson - Rh grouping
● Whole blood is used for standard transfusion until late 1970,
when component therapy began to take place
REPLACEMENT THERAPY
● Serologic compatibility for A, B, O, and Rh groups are
established routinely
● Cross-matching between donor’s red blood cells and
recipient’s sera (Major Crossmatch) is performed
● Rh negative individuals must be transfused only with Rh-
negative blood however may be given Rh-positive blood is
acceptable it Rh-negative blood is unavailable
○ Except for Rh-negative females who are of child-
bearing age (May cause Hemolytic Disease of the
Newborn)
● In emergency situations, type O-negative may be transfused
to all patients
● Patients with:
○ Cold agglutinins - Blood should be administered
with a blood warmer
○ Multiple transfusions and developed
alloantibodies or autoimmune hemolytic anemia
- Typing and Cross-matching is difficult, sufficient
time should be allotted preoperatively to
accumulate blood that might be required during the
operation
● Autologous transfusion is growing wherein the patient donates
and stores their own blood (if hemoglobin > 11g/dL or
hematocrit > 34%)
○ 1st procurement - 40 days before operation
○ Last is 3 days before operation
○ Donations is scheduled at intervals of 3-4 days
○ Recombinant human erythropoietin accelerates
generation of red blood cells and allows more
frequent harvesting of blood
BANKED WHOLE BLOOD
● Shelf life of 42 days
● Changes in red blood cells occurring during storage include
reduction of intracellular ADP and 2,3-diphosphoglycerate
(2,3-DPG)
○ Alters the oxygen dissociation curve of hemoglobin,
resulting in a decrease in oxygen transport.
● Stored RBCs progressively becomes acidotic with elevated
levels of lactate, potassium, and ammonia.
RED BLOOD CELLS AND FROZEN RED BLOOD CELLS
● RBC - product of choice for most clinical situations requiring
resuscitation
○ Supernatant plasma is removed from the red blood
cells after centrifugation
○ Reduced but does not eliminate reactions caused
by plasma components
Co, Loyola, Geronimo, Jazul, Larracas, Macario, Macam, Villanueva, Samson, Sy, Cordova,
S1 T2 | Barbosa, dela Torre, Soriano
● Frozen RBCs are not used in emergencies due to thawing and
preparation time is measured in hours.
○ Used for patients previously sensitized
○ RBC viability is improved, with the ATP and 2,3-
DPG concentrations maintained
LEUKOCYTE-REDUCED AND LEUKOCYTE-REDUCED/
WASHED RED BLOOD CELLS
● Leukocyte-reduced red blood cells are prepared by filtration
which removes 99.9% of WBS and most of platelets
○ Prevents febrile, nonhemolytic transfusion
reactions (fever and/or rigors), alloimmunization to
HLA class I antigens, and platelet transfusion
refractoriness and cytomegalovirus transmission
● Leukocyte-reduced/washed red blood cells are blood
products who have undergone additional saline washing
PLATELET CONCENTRATES
● Transfusion is indicated by qualitative platelet disorders and
thrombocytopenia caused by
○ Massive blood loss and replacement with platelet-
poor products
○ Inadequate production
● Shelf life of 120 hours from time of donation
● 1 unit is approximately 50 mL
● Platelet preparations are capable of transmitting infectious
diseases and can account for allergic reactions similar to
those caused by red blood cell transfusion
● A therapeutic level of platelets is in the range of 50,000 to
100,000/μL but is very dependent on the clinical situation
● Patients alloimmunized from previous transfusions or
refractory ue to prior pregnancies, HLA-matched platelets can
be used
FRESH FROZEN PLASMA
● Prepared from freshly donated blood
● Usual source of Vitamin K-dependent factors and only source
of factor V
● FFP can be thawed and stored up to 5 days, greatly increasing
its immediate availability
CONCENTRATES AND RECOMBINANT DNA TECHNOLOGY
● Technologic advancements have made the majority of clotting
factors and albumin readily available as concentrates.
○ These products are readily available and carry none
of the inherent infectious risks as other component
therapies.
INDICATIONS FOR REPLACEMENT OF BLOOD AND ITS
ELEMENTS
IMPROVEMENT OF OXYGEN-CARRYING CAPACITY
● Transfusion of red blood cells should augment oxygen
carrying capacity
○ Hemoglobin is fundamental to arterial oxygen
content and thus oxygen delivery
● However there is little evidence that equates transfusion of red
blood cells to enhanced cellular delivery and utilization
○ Due to changes that occur during blood storage
■ Decrease in 2,3-DPG and P50 impair
oxygen offloading
■ Deformation or RBC impairs
microcirculatory perfusion
TREATMENT OF ANEMIA
● Pre-operative red blood cell transfusion must be done in
patients with hemoglobin < 10 g/dl or hematocrit level < 30%
(1988 NIH Consensus Report)
○ Verified by a randomized control trial in critically ill
patients compared a restrictive transfusion
threshold to a more liberal strategy and
demonstrated that maintaining hemoglobin levels
between 7 and 9 g/dL had no adverse effect on
9 of 11
 SURGERY 1
Hemostasis, Surgical Bleeding and Transfusion
mortality. In fact, patients with APACHE II scores of
≤20 or patients age <55 years actually had a lower
mortality.
VOLUME REPLACEMENT
● Most common indication for blood transfusion in surgical
patients is the replenishment of blood volume
● Loss of blood in the operating room is roughly estimated by
amount of blood in e wound, on the drapes, weight of
sponges, and blood suctions from the operative field
● in patients with normal pre-operative values:
○ Blood loss up to 20% total blood volume can be
replaced with crystalloid or colloid solutions
○ > 20% blood loss may require addition of balance
resuscitation, including red blood cells, FFP, and
platelets
XIV. COMPLICATIONS OFTRANSFUSION
● Transfusion related complications are primarily due to blood
induced pro-inflammatory responses
NONHEMOLYTIC REACTIONS
● Febrile, non-hemolytic reactions - Increase in temperature
(>1°C) associated with a transfusion and are fairly common
○ Preformed cytokines in donor blood and recipient
antibodies are postulated etiologies
○ Reduced by pretreatment of acetaminophen and
use of leukocyte reduced blood products
● Bacterial contamination of infused blood is rare and may
cause sepsis and death
○ Gram negative are most common cause, capable
of growth at 4°C
○ Most cases are associated with administration of
platelets stored at 20°C or, even more commonly,
with apheresis platelets stored at room temperature
○ Clinical manifestations include fever and chills,
tachycardia, hypotension, and GI symptoms
○ If diagnosis is suspected, discontinue transfusion
and blood must be cultured
ALLERGIC REACTIONS
● Relatively frequent (1% in all transfusions)
● Reactions are usually mild and consists of rash, urticaria, and
flushing, rarely anaphylactic shock
○ Caused by transfusion of antibodies from
hypersensitive donors or the transfusion of antigens
to which the recipient is hypersensitive.
● Allergic reactions can occur after the administration of any
blood product but are commonly associated with FFP and
platelets
● Treatment and prophylaxis consist of the administration of
antihistamines
○ In more serious cases, epinephrine or steroids may
be indicated.
RESPIRATORY COMPLICATIONS
TRANSFUSION-ASSOCIATED CIRCULATORY OVERLOAD (TACO)
● Due to rapid infusion of blood, plasma expanders, and
crystalloids, particularly in older patients with underlying heart
disease
○ Central venous pressure monitoring done
whenever large amounts of fluid are administered.
● Overload is manifest by a rise in venous pressure, dyspnea,
and cough; Rales can be heard at the lung bases.
● Treatment consists of diuresis, slowing the rate of blood
administration, and minimizing fluids while blood products are
being transfused.
TRANSFUSION-RELATED ACUTE LUNG INJURY (TRALI)
● Defined as a non-cardiogenic pulmonary edema related to
transfusion
Co, Loyola, Geronimo, Jazul, Larracas, Macario, Macam, Villanueva, Samson, Sy, Cordova,
S1 T2 | Barbosa, dela Torre, Soriano
● Symptoms are similar to circulatory overload with dyspnea
and associated hypoxemia however is non-cardiogenic
● Characterized by fever, rigors, and bilateral pulmonary
infiltrates on chest x-ray
● Treatment of TRALI entails discontinuation of any transfusion,
notification of the transfusion service, and pulmonary support,
which may vary from supplemental oxygen to mechanical
ventilation.
HEMOLYTIC REACTIONS
● May be acute or delayed
● Contributing factors include errors in the laboratory of a
technical or clerical nature or the administration of the wrong
blood type
● Acute hemolytic reactions occur with the administration of
ABO-incompatible blood and can be fatal in up to 6% of cases.
○ Signs and symptoms include pain at the site of
transfusion, facial flushing, and back and chest
pain. Associated symptoms include fever,
respiratory distress, hypotension, and tachycardia.
■ In anesthetized patients, diffuse bleeding
and hypotension are the hallmarks
○ A positive Coombs’ test indicates transfused cells
coated with patient antibody and is diagnostic.
● Immediate hemolytic reactions are characterized by
intravascular destruction of red blood cells and consequent
hemoglobinemia and hemoglobinuria.
○ DIC can be initiated by antibody-antigen complexes
activating factor XII and complement, leading to
activation of the coagulation cascade.
○ Acute renal insufficiency results from the toxicity
associated with free hemoglobin in the plasma,
resulting in tubular necrosis and precipitation of
hemoglobin within the tubules
○ If suspected, immediately stop the transfusion,
send suspected unit of blood and patient sample to
the blood bank for comparison and Urine output
should be monitored with adequate hydration to
prevent precipitation of hemoglobin within the
tubules.
● Delayed hemolytic transfusion reactions occur 2 to 10 days
after transfusion and are characterized by extravascular
hemolysis, mild anemia, and indirect (unconjugated)
hyperbilirubinemia
○ Occurs when an individual has a low antibody titer
at the time of transfusion, but the titer increases
after transfusion as a result of an anamnestic
response
○ Reactions to non-ABO antigens involve
immunoglobulin G-mediated clearance by the
reticuloendothelial system.
○ Signs and symptoms include fever and recurrent
anemia, jaundice, decreased haptoglobin, with
low-grade hemoglobinemia and hemoglobinuria
TRANSMISSION OF DISEASE
● Malaria, Chagas’ disease, brucellosis, and, very rarely,
syphilis are among the diseases that have been transmitted
by transfusion.
○ Malaria, due to Plasmodium malariae, can be
transmitted in all blood components with initial
manifestations of shaking chills and spiking fever
● Transmission of hepatitis C and HIV-1 has been dramatically
minimized by the introduction of better antibody and nucleic
acid screening for these pathogens
10 of 11
 SURGERY 1
Hemostasis, Surgical Bleeding and Transfusion
XV. PRE- AND POST-LEC TEST
PRE TEST QUESTIONS
1-4. Give the 4 stages of hemostasis
5-7. Give 3 congenital factor deficiencies
8-9. Name 2 anti-coagulant meds
10. Name a complication of blood transfusion

Answers to Pretest
1-4
 Vascular Constriction
 Platelet Plug formation
 Fibrin Formation
 Fibrinolysis
5-7.
1. Coagulation Factor Deficiencies
a. Factor VIII deficiency (Hemophilia A , von Willebrand’s
disease)
b. Factor IX deficiency (Hemophilia B or Christmas
disease)
c. Factor XI deficiency
2. Platelet Functional Defects
8-9
 Heparin
 Low molecular weight heparins
 Warfarin
 Factor Xa inhibitors
 New direct thrombin inhibitors

10.
 Non hemolytic reactions
 Allergic reactions
 Respiratory Complications
 Hemolytic Reactions
 Transmission of Disease

REFERENCES:
1. Surgery trans - batch 2019
2. Schwartz
3. PPT ni Doc Aleta

Co, Loyola, Geronimo, Jazul, Larracas, Macario, Macam, Villanueva, Samson, Sy, Cordova,
S1 T2 | Barbosa, dela Torre, Soriano
11 of 11